ArticleCancer medicine2023

A real-world study of adjuvant anti-PD -1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations.

Wei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.